38226-10-7

Usage

Uses

Used in Pharmaceutical Industry:
2-FLUORO-6-HYDROXYBENZALDEHYDE is used as a key intermediate in the synthesis of aromatic compounds, specifically for the development of human Plasminogen Activator Inhibitor-1 (PAI-1) inhibitors. These inhibitors play a crucial role in the regulation of fibrinolysis, a process involved in the breakdown of blood clots. By targeting PAI-1, these compounds can potentially be used in the treatment of various thrombotic disorders and conditions related to impaired fibrinolysis.

InChI:InChI=1/C7H5FO2/c8-6-2-1-3-7(10)5(6)4-9/h1-4,10H

Upstream product

• 50-00-0 formaldehyd 
• 372-20-3 3-fluorophenol 
• 199388-02-8 2-fluoro-6-((tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde 
• 38226-08-3 3-Fluor-o-kresylacetat 
• 146137-74-8 2-fluoro-6-methoxybenzaldehyde 
• 446-52-6 2-Fluorobenzaldehyde 
• 67531-86-6 6-fluorosalicylic acid 
• 185913-28-4 2-(3-fluorophenoxy)tetrahydro-2H-pyran 

Downstream Products

• 38225-97-7 6-Fluor-3-nitrosalicylaldehyd 
• 38226-04-9 6-Fluor-5-nitrosalicylaldehyd 
• 187543-52-8 2-Fluoro-6-((R)-1-oxiranylmethoxy)-benzaldehyde 
• 187543-53-9 (R)-2-(2,3-epoxypropoxy)-6-fluorophenyl formate 
• 187543-55-1 (2R)-8-Fluoro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl 4-methylbenzenesulfonate 
• 126940-11-2 2-fluoro-6-methoxymethoxybenzaldehyde 
• 140675-43-0 2-Fluoro-6-hydroxybenzonitrile 
• 1227931-41-0 C₁₄H₁₂FN₃O 
• 1191038-89-7 C₈H₄F₄O₄S 
• 1382482-54-3 meso-3,4-bis(4-fluorophenyl)-1,6-bis(2-hydroxy-6-fluorophenyl)-2,5-diazahexa-1,5-diene 
• 1402602-63-4 trans-3-amino-1-cyclopropyl-3-(4-(10-fluoro-3-phenyl-5H-benzo[e]imidazo[1,2-c][1,3]oxazin-2-yl)phenyl)cyclobutanol 
• 1402602-64-5 trans-3-amino-3-(4-(10-fluoro-3-phenyl-5H-benzo[e]imidazo[1,2-c][1,3]oxazin-2-yl)phenyl)-1-methylcyclobutanol 
• 1446321-56-7 2-fluoro-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde 
• 82129-45-1 2-ethoxy-6-fluorobenzaldehyde 

Relevant academic research and scientific papers

Pd-Catalyzed Ortho C-H Hydroxylation of Benzaldehydes Using a Transient Directing Group

The direct Pd-catalyzed ortho C-H hydroxylation of benzaldehydes was achieved using 4-chloroanthranilic acid as the transient directing group, 1-fluoro-2,4,6-trimethylpyridnium triflate as the bystanding oxidant, and p-toluenesulfonic acid as the putative oxygen nucleophile. The unusual C-H chlorination and polyfluoroalkoxylation reactions signaled the importance of external nucleophiles to the outcome of Pd(IV) reductive eliminations.

C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF

This invention relates to a kind of C-aryl glycoside derivatives, its pharmaceutical compositions, preparation methods, and uses thereof. The preparation method comprises: method 1: in a solvent, deprotecting the acetyl protecting groups of compound 1-f in the presence of a base; method 2: 1) compound 2-g reacts with via Mitsunobu reaction; 2) deprotecting the acetyl protecting groups of compound 2-f obtained from step 1; method 3: 1) compound 2-g reacts with via nucleophilic substitution reaction; 2) deprotecting the acetyl protecting groups of compound 3-f obtained from step 1. The pharmaceutical composition comprises a kind of C-aryl glycoside derivatives; it's pharmaceutically acceptable salts and/or prodrugs thereof and excipient thereof. This invention further relates to a kind of C-aryl glycoside derivatives, it's pharmaceutically acceptable salts or pharmaceutical compositions thereof for the use in preparation of a SGLT inhibitor. The C-aryl glycoside derivatives of this invention provides a new direction for the study of SGLT inhibitors.

List fluoro Radicamine compounds and their use and preparation method

The invention discloses a mono-fluorinated Radicamine compound which has a structure as shown in a formula (1), and further provides a preparation method for the mono-fluorinated Radicamine compound with the structure as shown in the formula (1) and an application of the mono-fluorinated Radicamine compound or the mono-fluorinated Radicamine compound prepared with the method to preparation of drugs for preventing and/or treating diabetes, drugs for preventing and/or treating Gaucher's diseases, drugs for preventing and/or treating tumors or antiviral drugs. The mono-fluorinated Radicamine compound provided by the invention is good in glycosidase inhibition activity.

Fluorinated Radicamine A and B: Synthesis and Glycosidase Inhibition

Fluorinated derivatives of radicamine A and radicamine B have been synthesized from D-arabinose-derived cyclic nitrone. Structure-activity relationship studies showed that glycosidase inhibition of these fluorinated derivatives was significantly influenced by the position of the fluorine atom. C-7 or C-11 fluorination of the aromatic ring decreased α-glucosidase inhibition of the derivatives, whereas C-8 or C-10 fluorination preserved glycosidase inhibitory activities. Fluorinated derivatives of radicamine A and B have been synthesized from D-arabinose-derived cyclic nitrone. Structure-activity relationship studies revealed that glycosidase inhibition of these fluorinated derivatives was significantly influenced by the position of the fluorine atom.

PAI-1 INHIBITOR

The compound represented by the following formula (I) and the like have PAI-1 inhibition activity; wherein: R1 represents a C6-10 aryl group which may be substituted or the like; T represents a single bond or the like; m represents 0

Efficient and selective reduction protocols of the 2,2-dimethyl-1,3- benzodioxan-4-one functional group to readily provide both substituted salicylaldehydes and 2-hydroxybenzyl alcohols

Two complementary procedures have been developed that selectively allow for the synthesis of either substituted salicylaldehydes or the corresponding 2-hydroxylbenzyl alcohols upon treatment of the 2,2-dimethyl-1,3-benzodioxan-4- one functional group with DIBAL-H or LAH, respectively.

Non-metallocene compounds, method for the production thereof and use of the same for the polymerisation of olefins

The invention relates to a method for producing special transition metal compounds, to novel transition metal compounds and to the use of the same for the polymerisation of olefins.

Aminoalcohol derivatives

The present invention relates to a compound formula [I]: wherein R1 is hydrogen or halogen, R2 is hydrogen or an amino protective group, R3 is hydrogen or lower alkyl, X is bond, —CH2— or —O—, and Y is ?in which R4 is lower alkoxycarbonyl, ?in which R5 is carboxy(lower)alkyl, etc., ?in which R6 is hydroxy, etc., and so on, or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.

AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS

The present invention relates to a compound formula [I] or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.

Heterocyclcarboxamide derivatives and their use as therapeutic agents

Compounds of formula I STR1 and pharmaceutically acceptable salts thereof in which A is methylene or O; B is methylene or O; g is 0,1,2,3 or 4; R1 is an optional substituent; U is an alkylene chain optionally substituted by one or more alkyl; Q